Physician profile
Badar Anwar
NPI 1861443640
$5,846.09
in general payments reported to CMS, 2019-2025
35 companies · $628 in 2025
The $628 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $981 · 2021: $1,103 · 2022: $542 · 2023: $677 · 2024: $865 · 2025: $628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,150 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,150.11 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,438.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $693.32 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $478.83 | 2019-2024 | |
| Abbvie INC. | $384.59 | 2021-2024 | Ubrelvy |
| Astellas Pharma US INC | $276.97 | 2019-2025 | Veozah |
| Allergan, INC. | $276.91 | 2019-2020 | |
| Amarin Pharma, INC. | $225.93 | 2019-2021 | |
| Novo Nordisk INC | $211.59 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $201.44 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $194.90 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $155.41 | 2020-2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $152.13 | 2023-2025 | Rexulti, Abilify Maintena |
| Abbott Laboratories | $129.11 | 2021-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.18 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $101.75 | 2021-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.85 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $97.14 | 2019-2021 | |
| Esperion Therapeutics, INC. | $79.68 | 2024-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $56.09 | 2021-2024 | |
| Exact Sciences Corporation | $55.47 | 2023-2024 | Cologuard Collection Kit |
| Bausch Health US, LLC | $51.48 | 2022 | |
| Glaxosmithkline, LLC. | $45.23 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Dexcom, INC. | $45.19 | 2021-2022 | |
| Eisai INC. | $36.10 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $32.88 | 2021 | |
| Genentech USA, INC. | $30.81 | 2020 | |
| Horizon Therapeutics Plc | $30.57 | 2021 | |
| Intra-Sana Laboratories | $25.60 | 2024 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Jazz Pharmaceuticals INC. | $22.26 | 2020 | |
| Seqirus USA INC | $20.94 | 2025 | Fluad, Flucelvax |
| Viiv Healthcare Company | $20.75 | 2024 | Dovato |
| Daiichi Sankyo INC. | $19.68 | 2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $17.82 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $14.99 | 2025 | Gemtesa |
| Bardy Diagnostics, INC. | $12.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Badar Anwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.